Condition: Postpartum Depression · Sponsor: Nanjing Minova Pharmaceutical Co., Ltd.
This study is a multicenter, randomized, double-blind, placebo-controlled trial. It includes three groups. Each group will enroll 24 participants. The trial aims todetermine: To evaluate the efficacy of MI078 capsules in treating postpartum depression and to explore the optimal dosing regimen for MI078 capsules. To assess the safety of MI078 capsules in postpartum depression patients.
This description comes directly from the study's public registry record.
No contact information is available for this study as per the public registry record.
Always discuss trial participation with your own doctor first.
| The Affiliated Beijing Anding Hospital of Capital Medical University, Wuhu Hospital | Wuhu, Anhui, China | — |
| Beijing HuiLongGuan Hospital | Beijing, Beijing Municipality, China | — |
| Xiamen Xian Yue Hospital | Xiamen, Fujian, China | — |
| Shunde Hospital of Southern Medical University | Foshan, Guangdong, China | — |
| The First Affiliated Hospital of Jinan University | Guangzhou, Guangdong, China | — |
| Guangxi Zhuang Autonomous Region People's Hospital | Nanning, Guangxi, China | — |
| The People's Hospital of Guizhou Province | Guiyang, Guizhou, China | — |
| The First Hospital of Hebei Medical University | Shijiazhuang, Hebei, China | — |
| Xingtai People's Hospital | Xingtai, Hebei, China | — |
| The First Affiliated Hospital of Nanchang University | Nanchang, Jiangxi, China | — |
| Shanghai Mental Health Center | Shanghai, Shanghai Municipality, China | — |
| Shanghai Pudong New Area Mental Health Center | Shanghai, Shanghai Municipality, China | — |
+ 9 more locations — full list on the registry record.
Save your interest here for when the public record changes — results posted, or the study's status changes. Email alerts for this study aren't switched on yet.
We keep this only about this public record, and never email you without alerts being switched on. Want it removed at any time? Email hello@eichor.com. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.